JANX - NASDAQ

Janux Therapeutics, Inc.

JANX·NASDAQ

$13.95

+1.2%

HealthcareBiotechnology

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$850.45M

EPS-1.8300

P/E Ratio-7.62

Earnings Date08/06/2026

-82.23M

Operating Cash Flow

88%

3Y+92.0%

5Y+1782.0%

10Y+2048.0%

-300.98M

Investing Cash Flow

17%

3Y-617.0%

5Y-

10Y-

4.95M

Financing Cash Flow

-99%

3Y+889.0%

5Y-57.0%

10Y+24.0%

Janux Therapeutics, Inc. Cash Conversion Engine

JANX · NASDAQ

FCF Components

Net Income-113.62M

Depreciation & Amortization2.03M

Stock-Based Compensation40.22M

Change in Working Capital6.71M

Others-17.57M

Capital Expenditures-1.04M

Free Cash Flow-83.28M

Cash Flow Quality Analysis

FCF Conversion Rate

73.3%

Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.

CapEx Intensity

-1.3%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

-88.5%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

+$6.71M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Janux Therapeutics, Inc. Cash Flow Statement

JANX • NASDAQ

Janux Therapeutics, Inc. Cash Flow Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
OPERATING ACTIVITIES
Net Income	-113.6M	-69M	-58.3M	-63.1M	-32.7M	-6.8M	-4M
Depreciation & Amortization	2M	2.1M	2M	841K	113K	13K	6K
Stock-Based Compensation	40.2M	33M	20M	17.2M	6.9M	72K	6K
Other Non-Cash Items	-17.6M	-10.6M	-7.7M	-2.2M	-169K	1.9M	233K
Change in Working Capital	6.7M	685K	-6.6M	4.3M	8.8M	389K	-69K
Cash from Operating Activities	-82.2M	-43.8M	-50.6M	-42.9M	-17M	-4.4M	-3.8M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	-1M	-359K	-1.9M	-6.4M	-1.5M	(0.0)	(0.0)
Acquisitions, Net	(0.0)	(0.0)	(0.0)	-64.7M	(339.5M)	(0.0)	(0.0)
Purchase of Investments	-705.2M	-470.6M	-317.3M	-294.4M	-473.6M	(0.0)	(0.0)
Sale/Maturity of Investments	405.3M	212.9M	278M	359.1M	134.1M	0.0	0.0
Other Investing Items	0.0	0.0	0.0	64.7M	-339.5M	0.0	0.0
Cash from Investing Activities	-301M	-258M	-41.2M	(58.3M)	-341M	(0.0)	(0.0)
FINANCING ACTIVITIES
Net Issuance of Common Stock	4.9M	698.3M	56.5M	500K	204.2M	0.0	0.0
Net Issuance of Debt	0.0	0.0	0.0	0.0	0.0	2.5M	4M
Share Repurchases	-347K	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Other Financing Items	0.0	15M	3M	0.0	1.8M	70K	0.0
Cash from Financing Activities	4.9M	713.2M	59.5M	500K	386.5M	11.5M	4M
CASH FLOW SUMMARY
Net Change in Cash	-378.3M	411.4M	-32.2M	15.8M	28.6M	7.2M	172K
Cash at Beginning of Period	431.4M	20M	52.2M	36.4M	7.8M	658K	486K
Cash at End of Period	53.2M	431.4M	20M	52.2M	36.4M	7.8M	658K
Free Cash Flow	-83.3M	-44.2M	-52.4M	-49.4M	-18.5M	-4.4M	-3.8M

SEC Filings

JANX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 28, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 11, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 22, 2026	January 21, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 19, 2025	September 18, 2025	2025	View Filing

Showing 1 to 10 of 74 filings

Related Guides

Blog Categories

Continue your JANX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.